Ensign Peak Advisors Inc Trims Position in argenx SE (NASDAQ:ARGX)

Ensign Peak Advisors Inc cut its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 3.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,164 shares of the company's stock after selling 1,540 shares during the quarter. Ensign Peak Advisors Inc owned approximately 0.07% of argenx worth $24,701,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Stephens Inc. AR bought a new position in shares of argenx during the 4th quarter valued at about $310,000. Ritholtz Wealth Management increased its position in shares of argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock valued at $552,000 after purchasing an additional 414 shares during the last quarter. Jones Financial Companies Lllp increased its position in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after purchasing an additional 61 shares during the last quarter. Park Avenue Securities LLC increased its position in shares of argenx by 40.0% during the 4th quarter. Park Avenue Securities LLC now owns 1,695 shares of the company's stock valued at $1,042,000 after purchasing an additional 484 shares during the last quarter. Finally, Atomi Financial Group Inc. bought a new position in shares of argenx during the 4th quarter valued at about $339,000. 60.32% of the stock is currently owned by institutional investors.

argenx Trading Up 0.2%

NASDAQ:ARGX traded up $1.31 during trading hours on Friday, reaching $563.06. 293,152 shares of the company traded hands, compared to its average volume of 322,884. The business's 50-day moving average price is $591.92 and its two-hundred day moving average price is $612.84. The stock has a market capitalization of $34.38 billion, a P/E ratio of -640.63 and a beta of 0.57. argenx SE has a 1 year low of $356.38 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.26. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. As a group, equities analysts anticipate that argenx SE will post 3.13 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ARGX shares. Wedbush reiterated an "outperform" rating and issued a $715.00 price objective on shares of argenx in a research report on Friday, April 11th. Deutsche Bank Aktiengesellschaft upgraded argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. William Blair reiterated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Citigroup reiterated an "outperform" rating on shares of argenx in a research report on Wednesday. Finally, JMP Securities set a $699.00 price objective on argenx in a research report on Wednesday. One analyst has rated the stock with a hold rating, twenty have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $698.11.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.